RYTM
Rhythm Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.75B
P/E Ratio
—
EPS
$-3.11
Beta
2.14
52W High
$122.20
52W Low
$55.31
50-Day MA
$89.26
200-Day MA
$98.55
Dividend Yield
—
Profit Margin
-103.60%
Forward P/E
—
PEG Ratio
—
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | $189.76M |
| Gross Profit (TTM) | $170.26M |
| EBITDA | $-190.68M |
| Operating Margin | -82.20% |
| Return on Equity | -90.40% |
| Return on Assets | -27.50% |
| Revenue/Share (TTM) | $2.92 |
| Book Value | $2.07 |
| Price-to-Book | 41.33 |
| Price-to-Sales (TTM) | 30.29 |
| EV/Revenue | 28.95 |
| EV/EBITDA | -12.65 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 36.90% |
| Shares Outstanding | $68.28M |
| Float | $55.45M |
| % Insiders | 0.81% |
| % Institutions | 109.08% |
Historical Volatility
HV 10-Day
19.48%
HV 20-Day
47.95%
HV 30-Day
52.89%
HV 60-Day
49.66%
HV Rank
67.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($137.67 target)
4
Strong Buy11
Buy1
HoldData last updated: 4/29/2026